LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort

Photo from wikipedia

Factors associated with β-cell dysfunction in type 2 diabetes (T2D) are not well understood. We examined the association between OGTT-derived estimates of insulin sensitivity, insulin/C-peptide responses and β-cell function with… Click to show full abstract

Factors associated with β-cell dysfunction in type 2 diabetes (T2D) are not well understood. We examined the association between OGTT-derived estimates of insulin sensitivity, insulin/C-peptide responses and β-cell function with baseline phenotypic characteristics in the GRADE cohort. The cohort comprised 5,047 adults with T2D 2 , weight 99.9±22.3 kg, waist circumference (circ) 112.3±15.8 cm, HbA1c 7.5±0.5% and T2D duration 4.2±2.8 y. Racial composition was 66% white, 20% African Americans, 4% Asian, 3% American Indian, and 7% Other. Insulin sensitivity did not differ between men and women, but women had higher insulin/C-peptide responses and disposition index (DI) (p In summary, among GRADE participants, sex, race and obesity are associated with β-cell function. Although statistically significant, the associations of insulin sensitivity and β-cell responses with age and T2D duration are not as strong. Disclosure N. Rasouli: Consultant; Self; AstraZeneca, Intarcia Therapeutics, Inc. R.M. Cohen: Stock/Shareholder; Self; Bristol-Myers Squibb Company. R.A. DeFronzo: Speaker9s Bureau; Self; AstraZeneca, Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca, Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Elcelyx Therapeutics, Inc., Intarcia Therapeutics, Inc.. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc. S. Inzucchi: Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca, Novo Nordisk Inc., Sanofi, Lexicon Pharmaceuticals, Inc.. Consultant; Self; VTV Therapeutics. Other Relationship; Self; Intarcia Therapeutics, Inc.. Consultant; Self; Janssen Pharmaceuticals, Inc., Alere Inc.. F. Ismail-Beigi: None. S.E. Kahn: Advisory Panel; Self; Boehringer Ingelheim GmbH, Elcelyx Therapeutics, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Research & Development, Merck & Co., Inc., Novo Nordisk A/S. K. Utzschneider: Consultant; Self; Novo Nordisk Inc. J. Lachin: Board Member; Self; AbbVie Inc., Celgene Corporation. N. Younes: None. G. Research Group: Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute. Other Relationship; Self; Bristol-Myers Squibb Company, Merck & Co., Inc., Novo Nordisk Inc., Sanofi-Aventis, Roche Diagnostics Corporation, Becton, Dickinson and Company, Centers for Disease Control and Prevention, National Diabetes Education Program.

Keywords: pharmaceuticals inc; self; novo nordisk; therapeutics inc; insulin sensitivity

Journal Title: Diabetes
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.